VC fund profile · evidence-aware directory data
Advent Life Sciences Fund IV stages, portfolio and investment profile
Early-stage biotech and healthcare venture vehicle; British Business Bank agreed to an approximately €69.8M LP commitment on September 24, 2026 (converted estimate). Its institutional listing gives roughly €291M as a fundraising target, not funds raised. No first or final close was verified.
Keep track of Advent Life Sciences Fund IV
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$1M–$10M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Seed, Series A, Series B
Sector focus
Not recorded
Geography
London, UK
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
VCT investor research
Inside Advent Life Sciences Fund IV's investment strategy
Independent, source-backed analysis of who the firm backs, deal evidence and whether it fits your stage.
Mandate
Separate from the manager's Growth Fund, Fund IV backs earlier-stage therapeutics, medtech and enabling healthcare platforms targeting major clinical needs. Geography is transatlantic.
Capital, target and status
The British Business Bank institutional profile shows a roughly €291M fundraising target, converted using the September 24 ECB fixing (1 EUR = 0.85986 in original currency). It agreed to commit approximately €69.8M. The GP's full commitments, legal closing stage and actual close date are not disclosed; an agreement is not final close. No other institutional LP amounts are confirmed.
Founder and LP fit
An illustrative early-stage company would demonstrate patent ownership, target/assay validation, preclinical reproducibility, milestone timeline and follow-on financing requirements. Neither a standard check size nor fee/carry, ownership target or fund return has been verified. Professional/institutional investor access is subject to private fund marketing rules, not retail subscriptions.
Related manager, Growth Fund. Sources: bank release; vehicle listing; ECB.
Sources and verification
Dated company disclosures take priority over third-party databases. These sources support the analysis above.
Rounds they lead
Rounds they invest
Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.